Vividion Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 270

Employees

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Latest Deal Amount
  • $100M

Vividion Therapeutics General Information

Description

Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses. The company's platform applies chemical proteomics to expand the druggable proteome and addresses difficult targets providing transformative treatments, enabling healthcare professionals to eliminate artifacts and create proteome-wide drug interaction maps, for simultaneous target engagement and global selectivity profiling.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 5820 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 5820 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vividion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 20-Aug-2021 $100M Cancelled Generating Revenue
7. Merger/Acquisition 01-Aug-2021 Completed Generating Revenue
6. Later Stage VC (Series C) 01-Feb-2021 Completed Generating Revenue
5. Later Stage VC (Series B) 30-Apr-2019 Completed Generating Revenue
4. Early Stage VC 05-Mar-2018 Completed Generating Revenue
3. Early Stage VC (Series A3) 24-Oct-2017 Completed Generating Revenue
2. Early Stage VC (Series A2) 02-Feb-2017 $50M $53.5M Completed Generating Revenue
1. Early Stage VC (Series A) 11-Apr-2016 $3.5M $3.5M Completed Generating Revenue
To view Vividion Therapeutics’s complete valuation and funding history, request access »

Vividion Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A-3
Series A-2 67,333,334 $0.001000 6% $0.6 $0.6 1x $0.6 24.17%
Series A 18,118,465 $0.001000 6% $0.25 $0.25 1x $0.25 6.5%
To view Vividion Therapeutics’s complete cap table history, request access »

Vividion Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnes
Drug Discovery
San Diego, CA
270 As of 2025

Boulder, CO
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vividion Therapeutics Competitors (130)

One of Vividion Therapeutics’s 130 competitors is Enveda, a Venture Capital-Backed company based in Boulder, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enveda Venture Capital-Backed Boulder, CO
TriGemX Bio Venture Capital-Backed New York, NY
Abcuro Venture Capital-Backed Newton, MA
InterAx Venture Capital-Backed Schlieren, Switzerland
Exo Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 130 competitors. Get the full list »

Vividion Therapeutics Patents

Vividion Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026206950-A1 (s,e)-n-(1-cyclopropyl-3-(methylsulfonyl)allyl)-2-(1,1-difluoroethyl)-4-phenoxypyrimidine-5-carboxamide for treating cancer Pending 24-Mar-2025
WO-2026206763-A1 Compounds and methods for modulating ras-pi3k Pending 24-Mar-2025
WO-2026128789-A1 Keap1 inhibitors and uses thereof Pending 13-Dec-2024
WO-2026128791-A1 Keap1 inhibitors and uses thereof Pending 13-Dec-2024
US-20250228866-A1 Crystalline form of (r)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-one Pending 10-Jun-2024 A61K31/5377
To view Vividion Therapeutics’s complete patent history, request access »

Vividion Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vividion Therapeutics Former Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Acuta Capital Partners Hedge Fund Minority
Alexandria Venture Investments Venture Capital Minority
Altitude Life Science Ventures Venture Capital Minority
Avoro Capital Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Vividion Therapeutics Investments & Acquisitions (2)

Vividion Therapeutics’s most recent deal was a Corporate Asset Purchase with Roche (Werner Helicase Inhibitor Rights). The deal was made on 04-Jun-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Roche (Werner Helicase Inhibitor Rights) 04-Jun-2025 Corporate Asset Purchase Buildings and Property
Tavros Therapeutics 23-Dec-2024 Merger/Acquisition Drug Discovery
To view Vividion Therapeutics’s complete investments and acquisitions history, request access »

Vividion Therapeutics FAQs

  • When was Vividion Therapeutics founded?

    Vividion Therapeutics was founded in 2013.

  • Where is Vividion Therapeutics headquartered?

    Vividion Therapeutics is headquartered in San Diego, CA.

  • What is the size of Vividion Therapeutics?

    Vividion Therapeutics has 270 total employees.

  • What industry is Vividion Therapeutics in?

    Vividion Therapeutics’s primary industry is Drug Discovery.

  • Is Vividion Therapeutics a private or public company?

    Vividion Therapeutics is a Private company.

  • What is Vividion Therapeutics’s current revenue?

    The current revenue for Vividion Therapeutics is .

  • How much funding has Vividion Therapeutics raised over time?

    Vividion Therapeutics has raised $379M.

  • Who are Vividion Therapeutics’s investors?

    ARCH Venture Partners, Acuta Capital Partners, Alexandria Venture Investments, Altitude Life Science Ventures, and Avoro Capital are 5 of 23 investors who have invested in Vividion Therapeutics.

  • Who are Vividion Therapeutics’s competitors?

    Enveda, TriGemX Bio, Abcuro, InterAx, and Exo Therapeutics are some of the 130 competitors of Vividion Therapeutics.

  • When was Vividion Therapeutics acquired?

    Vividion Therapeutics was acquired on 20-Aug-2021.

  • Who acquired Vividion Therapeutics?

    Vividion Therapeutics was acquired by Bayer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process